Kyle J. MacBeth

4.3k total citations
45 papers, 1.6k citations indexed

About

Kyle J. MacBeth is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Kyle J. MacBeth has authored 45 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 18 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Kyle J. MacBeth's work include Acute Myeloid Leukemia Research (28 papers), Histone Deacetylase Inhibitors Research (8 papers) and Epigenetics and DNA Methylation (7 papers). Kyle J. MacBeth is often cited by papers focused on Acute Myeloid Leukemia Research (28 papers), Histone Deacetylase Inhibitors Research (8 papers) and Epigenetics and DNA Methylation (7 papers). Kyle J. MacBeth collaborates with scholars based in United States, France and Italy. Kyle J. MacBeth's co-authors include Carla Heise, Hagop M. Kantarjian, Aaron Nguyen, Tao Shi, Eric Laille, Guillermo Garcia‐Manero, Steven D. Gore, Christopher R. Cogle, Yuhong Ning and Sharon L. Aukerman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Kyle J. MacBeth

45 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kyle J. MacBeth United States 21 1.0k 950 324 258 193 45 1.6k
A Henri France 21 795 0.8× 559 0.6× 377 1.2× 110 0.4× 155 0.8× 51 1.6k
Marina Parry United Kingdom 16 245 0.2× 382 0.4× 110 0.3× 171 0.7× 54 0.3× 34 1.0k
Nora‐Athina Viniou Greece 14 321 0.3× 299 0.3× 145 0.4× 165 0.6× 69 0.4× 64 789
Bronwyn M. Owens United States 12 372 0.4× 807 0.8× 68 0.2× 299 1.2× 91 0.5× 15 2.0k
Ivan Lončarević Germany 18 242 0.2× 353 0.4× 110 0.3× 79 0.3× 108 0.6× 41 902
Stephen D. Smith United States 21 268 0.3× 253 0.3× 579 1.8× 743 2.9× 122 0.6× 125 1.6k
Jill R. Storry United States 21 1.2k 1.1× 273 0.3× 399 1.2× 48 0.2× 81 0.4× 104 1.7k
Dale R. Taylor United Kingdom 9 229 0.2× 522 0.5× 87 0.3× 285 1.1× 121 0.6× 12 1.6k
Ronald Billing United States 21 505 0.5× 542 0.6× 171 0.5× 200 0.8× 183 0.9× 74 1.6k
David Tamang United States 14 362 0.4× 1.3k 1.4× 49 0.2× 637 2.5× 87 0.5× 37 1.8k

Countries citing papers authored by Kyle J. MacBeth

Since Specialization
Citations

This map shows the geographic impact of Kyle J. MacBeth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle J. MacBeth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle J. MacBeth more than expected).

Fields of papers citing papers by Kyle J. MacBeth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle J. MacBeth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle J. MacBeth. The network helps show where Kyle J. MacBeth may publish in the future.

Co-authorship network of co-authors of Kyle J. MacBeth

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle J. MacBeth. A scholar is included among the top collaborators of Kyle J. MacBeth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle J. MacBeth. Kyle J. MacBeth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
MacBeth, Kyle J., Vivek S. Chopra, Lin Tang, et al.. (2021). Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA. Experimental Hematology. 98. 47–52.e6. 8 indexed citations
2.
Stein, Eytan M., Amir T. Fathi, Courtney D. DiNardo, et al.. (2020). Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. The Lancet Haematology. 7(4). e309–e319. 79 indexed citations
3.
Platzbecker, Uwe, Alberto Risueño, Esther T. Chan, et al.. (2020). Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial. Blood. 136(Supplement 1). 38–39. 2 indexed citations
4.
Levy, Benjamin, Giuseppe Giaccone, Benjamin Besse, et al.. (2019). Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. European Journal of Cancer. 108. 120–128. 48 indexed citations
5.
Pollyea, Daniel A., Martin S. Tallman, Stéphane de Botton, et al.. (2019). Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 33(11). 2575–2584. 165 indexed citations
6.
Cathelin, Séverine, David Sharon, Dan Cojocari, et al.. (2018). Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models. Blood. 132(Supplement 1). 562–562. 23 indexed citations
7.
Döhner, Hartmut, Anna Dolnik, Lin Tang, et al.. (2018). Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 32(12). 2546–2557. 82 indexed citations
8.
Fang, Jing, Xiaona Liu, Lyndsey Bolanos, et al.. (2016). A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Nature Medicine. 22(7). 727–734. 63 indexed citations
9.
10.
Therrien, Éric, Natalie Nguyen, Jubrail Rahil, et al.. (2015). Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(12). 2514–2518. 23 indexed citations
11.
Laille, Eric, Tao Shi, Guillermo Garcia‐Manero, et al.. (2015). Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PLoS ONE. 10(8). e0135520–e0135520. 48 indexed citations
12.
Garcia‐Manero, Guillermo, Steven D. Gore, Suman Kambhampati, et al.. (2015). Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 30(4). 889–896. 86 indexed citations
13.
Saft, Leonie, Masoud Karimi, Mehran Ghaderi, et al.. (2014). p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 99(6). 1041–1049. 97 indexed citations
14.
Giagounidis, Aristoteles, Ghulam J. Mufti, Pierre Fenaux, et al.. (2013). Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Annals of Hematology. 93(1). 1–11. 31 indexed citations
15.
Hollenbach, Paul W., Aaron Nguyen, Helen Brady, et al.. (2010). A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines. PLoS ONE. 5(2). e9001–e9001. 288 indexed citations
16.
Buglio, Daniela, Vidya Mamidipudi, Noor M. Khaskhely, et al.. (2010). The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism. British Journal of Haematology. 151(4). 387–396. 44 indexed citations
17.
18.
Guo, An‐Yuan, Karsten Becker, Hava T. Siegelmann, et al.. (2003). Microarray analysis of global gene expression in the mammary gland following estrogen and progesterone treatment of ovariectomized mice.. Cancer Epidemiology Biomarkers & Prevention. 12(11). 1 indexed citations
19.
MacBeth, Kyle J., et al.. (1997). Cleavage Site Mapping and Substrate-Specificity of Leishmaniavirus 2-1 Capsid Endoribonuclease Activity. The Journal of Biochemistry. 122(1). 193–200. 7 indexed citations
20.
MacBeth, Kyle J. & Jean L. Patterson. (1995). The short transcript of Leishmania RNA virus is generated by RNA cleavage. Journal of Virology. 69(6). 3458–3464. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A Henri Breakdown of academic impact, for papers by Marina Parry Breakdown of academic impact, for papers by Nora‐Athina Viniou Breakdown of academic impact, for papers by Bronwyn M. Owens Breakdown of academic impact, for papers by Ivan Lončarević Breakdown of academic impact, for papers by Stephen D. Smith Breakdown of academic impact, for papers by Jill R. Storry Breakdown of academic impact, for papers by Dale R. Taylor Breakdown of academic impact, for papers by Ronald Billing Breakdown of academic impact, for papers by David Tamang
Rankless by CCL
2026